{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:30:26Z","timestamp":1790998226031,"version":"4.1.0"},"reference-count":93,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Antiphospholipid syndrome (APS) can affect the kidneys, leading to renal artery and vein thrombosis, allograft loss following transplantation, and microvascular damage referred to as aPL-nephropathy (aPL-N). APL-N is a complex and frequently underdiagnosed condition characterized by an incomplete understanding of its etiopathogenesis and associated with unfavorable renal outcomes. The 2023 ACR\/EULAR classification criteria for APS included aPL-N within the microvascular domain. The gold standard for aPL-N is the biopsy, revealing lesions associated with acute thrombotic microangiopathy and chronic vascular changes. Nevertheless, reluctance for biopsies due to anticoagulation and thrombocytopenia underscores the need for noninvasive diagnostics. Common clinical features include hypertension, microscopic hematuria, proteinuria, and renal insufficiency. Antiphospholipid antibodies seem crucial to kidney damage through thrombotic and inflammatory processes. Studies and experimental models of thrombotic microangiopathy lesions suggest the involvement of the complement cascade, tissue factor, and mammalian target of the rapamycin complex activation pathway. Currently, the management of aPL-N is based mainly on expert opinion, with limited evidence supporting the use of anticoagulants, leading to controversy in their application. Treatment may include heparin, intravenous immunoglobulin, plasma exchange, and targeted therapies tailored to aPL-N mechanisms. Future multicenter studies are essential to clarify their roles. The goal of this review is to inform clinicians and create a research agenda to address the unmet needs in diagnosing and managing APL-N.<\/jats:p>","DOI":"10.3390\/jcm14103326","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:13:38Z","timestamp":1747041218000},"page":"3326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perspective on Renal Involvement in Antiphospholipid Syndrome: Implications for Diagnosis, Pathogenesis, and Treatment"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-6432","authenticated-orcid":false,"given":"Ariela","family":"Hoxha","sequence":"first","affiliation":[{"name":"Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine\u2014DIMED, University of Padua, Via Giustiniani 2, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-3472","authenticated-orcid":false,"given":"Dorella","family":"Del Prete","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Department of Medicine, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Condonato","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine\u2014DIMED, University of Padua, Via Giustiniani 2, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2402-9276","authenticated-orcid":false,"given":"Francesca K.","family":"Martino","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Department of Medicine, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0845-8515","authenticated-orcid":false,"given":"Marco","family":"Lovisotto","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine\u2014DIMED, University of Padua, Via Giustiniani 2, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-2764","authenticated-orcid":false,"given":"Federico","family":"Nalesso","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Department of Medicine, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-383X","authenticated-orcid":false,"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine\u2014DIMED, University of Padua, Via Giustiniani 2, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e069717","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: Advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"11","author":"Schreiber","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.autrev.2006.06.005","article-title":"The catastrophic antiphospholipid (Asherson\u2019s) syndrome","volume":"6","author":"Asherson","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103180","DOI":"10.1016\/j.jaut.2024.103180","article-title":"Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study","volume":"144","author":"Hoxha","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"sfae302","DOI":"10.1093\/ckj\/sfae302","article-title":"Antiphospholipid antibodies nephropathy is associated with an increased risk of kidney failure: A systematic literature review and meta-analysis","volume":"17","author":"Hoxha","year":"2024","journal-title":"Clin. Kidney. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103072","DOI":"10.1016\/j.autrev.2022.103072","article-title":"Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management","volume":"21","author":"Scheen","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0961203310397410","article-title":"Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus","volume":"20","author":"Sant","year":"2011","journal-title":"Lupus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s10067-023-06699-1","article-title":"Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature","volume":"42","author":"Ruffatti","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients: Clinical and immunologic manifestations of APS","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis. Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00460110","article-title":"Renal involvement in primary antiphospholipid syndrome: Retrospective analysis of 160 patients","volume":"5","author":"Sinico","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ekir.2023.01.018","article-title":"Clinical-pathological characteristics of renal injuries identify different clusters in patients with antiphospholipid antibodies","volume":"8","author":"Sciascia","year":"2023","journal-title":"Kidney. Int. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the \u201cCAPSregistry\u201d","volume":"32","author":"Cervera","year":"2009","journal-title":"J. Autoimmun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2019001530","article-title":"Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis","volume":"134","author":"Hollerbach","year":"2019","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2010-07-299099","article-title":"Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome","volume":"117","author":"Urbanus","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis. Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1196\/annals.1422.058","article-title":"C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies","volume":"1108","author":"Liu","year":"2007","journal-title":"Ann. New York Acad. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","article-title":"Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies","volume":"114","author":"Seshan","year":"2009","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1681\/ASN.V94590","article-title":"CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats","volume":"9","author":"Nangaku","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1681\/ASN.2014050429","article-title":"Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy","volume":"26","author":"Chua","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/0961203310368409","article-title":"Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: A prospective study of 155 cases","volume":"19","author":"Shen","year":"2010","journal-title":"Lupus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis. Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/ard.49.3.184","article-title":"Renal-artery thrombosis and hypertension in a 13-year-old girl with antiphospholipid syndrome","volume":"49","author":"Ostuni","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tektonidou, M.G. (2018). Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01181"},{"key":"ref_30","first-page":"1181","article-title":"Renal involvement in primary antiphospholipid syndrome","volume":"19","author":"Amigo","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_31","first-page":"1802","article-title":"Bilateral renal artery occlusion in a patient with primary antiphospholipid antibody syndrome: Thrombosis, vasculitis or both?","volume":"19","author":"Ames","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard.62.10.999","article-title":"Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension","volume":"62","author":"Sangle","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.semnephrol.2011.05.007","article-title":"Imaging for renovascular disease","volume":"31","author":"Bardelli","year":"2011","journal-title":"Semin. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4329\/wjr.v9.i1.10","article-title":"Impact of contrast-enhanced ultrasound in patients with renal function impairment","volume":"9","author":"Girometti","year":"2017","journal-title":"World J. Radiol."},{"key":"ref_35","first-page":"1929","article-title":"Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome","volume":"10","author":"Ko","year":"1995","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1464-410X.1994.tb07137.x","article-title":"Renal vein thrombosis caused by primary antiphospholipid syndrome","volume":"74","author":"Morgan","year":"1994","journal-title":"Br. J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00467-011-1787-z","article-title":"Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy","volume":"26","author":"Chaturvedi","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0961203311430220","article-title":"Renal transplantation in lupus nephritis: A Brazilian cohort","volume":"21","author":"Oliveira","year":"2012","journal-title":"Lupus"},{"key":"ref_39","first-page":"288","article-title":"Computed tomography of renal vein thrombosis","volume":"8","author":"Glazer","year":"1984","journal-title":"J. Comput. Assist. Tomogr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.V103507","article-title":"The intrarenal vascular lesions associated with primary antiphospholipid syndrome","volume":"10","author":"Nochy","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_41","first-page":"1983","article-title":"Antiphospholipid Syndrome (APS) nephropathy in catastrophic, primary and systemic lupus erythematosus-related APS","volume":"35","author":"Tektonidou","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome","volume":"50","author":"Tektonidou","year":"2004","journal-title":"Arthritis. Rheum."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/0961203317692419","article-title":"Prognostic significance of renal vascular pathology in lupus nephritis","volume":"26","year":"2017","journal-title":"Lupus"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40620-020-00938-3","article-title":"Renal thrombotic microangiopathy associated to worse renal prognosis in Lupus Nephritis","volume":"34","author":"Strufaldi","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ajkd.2003.09.011","article-title":"Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis","volume":"43","author":"Moroni","year":"2004","journal-title":"Am. J. Kidney. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","article-title":"Efforts to Better Characterize \u201cAntiphospholipid Antibody Nephropathy\u201d for the 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report","volume":"51","author":"Barbhaiya","year":"2024","journal-title":"J. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jmri.28565","article-title":"Noninvasive Assessment of the Renal Function, Oxford Classification and Prognostic Risk Stratification of IgAN by Using Intravoxel Incoherent Motion Diffusion-Weighted Imaging and Blood Oxygenation Level-Dependent MRI","volume":"58","author":"Liang","year":"2023","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0272-6386(03)00352-4","article-title":"The expanding spectrum of renal diseases associated with antiphospholipid syndrome","volume":"41","author":"Fakhouri","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0272-6386(99)70009-0","article-title":"Antiphospholipid antibody syndrome in renal transplantation: Occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus","volume":"34","author":"Stone","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1600-6143.2010.03233.x","article-title":"Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies","volume":"10","author":"Canaud","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ndt\/gfx353","article-title":"Anti-cardiolipin antibodies and 12-month graft function in kidney transplant recipients: A prognosis cohort survey","volume":"33","author":"Gauthier","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1399-0012.2012.01625.x","article-title":"Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome","volume":"26","author":"Vaidya","year":"2012","journal-title":"Clin. Transpl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0041-1345(98)01629-7","article-title":"Antiphospholipid antibodies are a risk factor for early renal allograft failure: Isolation of antiphospholipid antibodies from a thrombosed renal allograft","volume":"31","author":"Wagenknecht","year":"1999","journal-title":"Transplant. Proc."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Furma\u0144czyk-Zawiska, A., Bu\u0142\u0142o-Piontecka, B., Komorniczak, M., D\u0119bska-\u015alizie\u0144, A., Augustyniak-Bartosik, H., and Durlik, M. (2023). Antiphospholipid Syndrome in Renal Allograft Recipients-A Long-Term Multicenter Analysis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12020667"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1161\/CIRCULATIONAHA.116.025992","article-title":"\u03b22-Glycoprotein I\/IgA Immune Complexes: A Marker to Predict Thrombosis After Renal Transplantation in Patients With Antiphospholipid Antibodies","volume":"135","author":"Serrano","year":"2017","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1515\/cclm-2014-1129","article-title":"Relationship between antiphosphatidylserine\/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome","volume":"53","author":"Hoxha","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/0961203312441983","article-title":"Antiphosphatidylserine\/prothrombin antibodies in primary antiphospholipid syndrome","volume":"21","author":"Hoxha","year":"2012","journal-title":"Lupus"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/rheumatology\/keh490","article-title":"Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: Outcome following anticoagulation","volume":"44","author":"Sangle","year":"2005","journal-title":"Rheumatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1177\/0961203314538687","article-title":"Identification and treatment of APS renal involvement","volume":"23","author":"Tektonidou","year":"2014","journal-title":"Lupus"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1191\/0961203303lu461oa","article-title":"Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy","volume":"12","author":"Korkmaz","year":"2003","journal-title":"Lupus"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2015.08.010","article-title":"Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review","volume":"15","author":"Kronbichler","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaut.2018.07.001","article-title":"Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report","volume":"93","author":"Ruffatti","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis. Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0961203311400115","article-title":"Treatment-induced downregulation of antiphospholipid antibodies: Effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome","volume":"20","author":"Sciascia","year":"2011","journal-title":"Lupus"},{"key":"ref_70","first-page":"215","article-title":"Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab","volume":"14","author":"Tsagalis","year":"2010","journal-title":"Hippokratia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/0961203316682102","article-title":"Belimumab in primary antiphospholipid syndrome","volume":"26","author":"Yazici","year":"2017","journal-title":"Lupus"},{"key":"ref_72","first-page":"597","article-title":"Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and\/or non-criteria manifestations of antiphospholipid syndrome: Study protocol","volume":"41","author":"Sciascia","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: A case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"\u00c1vila, A., Gavela, E., and Sancho, A. (2021). Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front. Med., 8.","DOI":"10.3389\/fmed.2021.642864"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the \u201cCAPS Registry\u201d","volume":"21","author":"Amigo","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/annrheumdis-2016-209442","article-title":"Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome","volume":"76","author":"Grenn","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Cecchi, I., Radin, M., Barinotti, A., Foddai, S.G., Menegatti, E., Roccatello, D., Su\u00e1rez, A., Sciascia, S., and Rodr\u00edguez-Carrio, J. (2024). Type I interferon pathway activation across the antiphospholipid syndrome spectrum: Associations with disease subsets and systemic antiphospholipid syndrome presentation. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1351446"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102978","DOI":"10.1016\/j.jaut.2022.102978","article-title":"Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome","volume":"134","author":"Verrou","year":"2023","journal-title":"J. Autoimmun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5568822","DOI":"10.1155\/mi\/5568822","article-title":"Inhibiting Tyrosine Kinase 2 Ameliorates Antiphospholipid Syndrome Nephropathy","volume":"2024","author":"Tang","year":"2024","journal-title":"Mediators. Inflamm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ajkd.2023.02.003","article-title":"KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"82","author":"Beck","year":"2023","journal-title":"Am. J. Kidney. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.kint.2023.10.009","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney. Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: Thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood. Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mri.2023.07.002","article-title":"Diffusion-weighted, intravoxel incoherent motion, and diffusion kurtosis tensor MR imaging in chronic kidney diseases: Correlations with histology","volume":"106","author":"Zhu","year":"2024","journal-title":"Magn. Reson. Imaging."},{"key":"ref_88","first-page":"e920232","article-title":"Diffusion Weighted Magnetic Resonance Imaging in the Assessment of Renal Function and Parenchymal Changes in Chronic Kidney Disease: A Preliminary Study","volume":"25","author":"Palczewski","year":"2020","journal-title":"Ann. Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1093\/rheumatology\/keae397","article-title":"Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression","volume":"63","author":"Tektonidou","year":"2024","journal-title":"Rheumatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"SI4","DOI":"10.1093\/rheumatology\/kead603","article-title":"Antiphospholipid syndrome pathogenesis in 2023: An update of new mechanisms or just a reconsideration of the old ones?","volume":"63","author":"Raschi","year":"2024","journal-title":"Rheumatology"},{"key":"ref_91","first-page":"2088","article-title":"High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets","volume":"40","author":"Ruffatti","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood.2020010575","article-title":"Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome","volume":"137","author":"Ruffatti","year":"2021","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.thromres.2022.05.001","article-title":"Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome","volume":"214","author":"Mazetto","year":"2022","journal-title":"Thromb. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:35Z","timestamp":1760031035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":93,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14103326"],"URL":"https:\/\/doi.org\/10.3390\/jcm14103326","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]}}}